Clinical Outcomes after Percutaneous Coronary Intervention with Drug-Eluting Stents in Dialysis Patients

Volume 18 - Issue 6 - June, 2006
Posted on: 8/1/08
0 Comments
3108 reads

Author(s):

Salah-Eddine Hassani, MD, William W. Chu, MD, PhD, Roswitha M. Wolfram, MD,
Pramod K. Kuchulakanti, MD, Zhenyi Xue, MS, Natalie Gevorkian, MD, William O. Suddath, MD, Lowell F. Satler, MD, Kenneth M. Kent, MD, PhD, Augusto D. Pichard, MD, Neil J. Weissman, MD, Ron Waksman, MD

The major cause of mortality in dialysis patients is attributable to cardiovascular diseases.^1,2 The higher prevalence of coronary artery disease in this population is thought to be related to a higher risk factor distribution, platelet thrombogenicity and premature coronary calcification, when compared with nondialysis subjects. Treatment of ischemic heart disease with percutaneous revascularization techniques has remained controversial because of consistent exclusion of dialysis patients from major clinical trials. To our knowledge, the literature has been composed of retrospective, single-institution experiences with only small numbers of patients, and has led to the conclusion that percutaneous coronary intervention (PCI) in dialysis patients is less successful and associated with more adverse outcomes when compared to nondialysis patients.^3,4 Drug-eluting stents (DES) have recently proven an impressive tool in the reduction of repeat revascularization in the overall population and clinical indications. The aim of the present study was to evaluate the outcomes of dialysis versus nondialysis patients treated with PCI and DES.